Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 19, 2020Journal of Clinical OncologyOpen Access

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDavid P. SteensmaPFPierre FenauxKEKoen Van Eygen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Steensma et al. (2020) studied this question.

synapsesocial.com/papers/69dffb672833447a7e255d2fhttps://doi.org/10.1200/jco.20.01895
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life2003 · 458 citations
  2. 2Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B2002 · 1,830 citations
  3. 3Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?2013 · 79 citations
  4. 4Treatment of MDS2019 · 244 citations